Edgar Filing: KAILIAN VAUGHN M - Form 4

KAILIAN V Form 4	VAUGHN M										
February 11	, 2014										
FORM	ЛΔ								OMB A	PROVAL	
		SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					OMB Number:	3235-0287			
Check tl if no lon subject t Section Form 4 e Form 5 obligatio	F CHANGES IN BENEFICIAL OWN SECURITIES Section 16(a) of the Securities Exchange					Act of 1934,	Estimated average burden hours per response				
may con <i>See</i> Instr 1(b).	ruction			•	ding Com t Company	• •		1935 or Sectior)	I		
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> MPM BioVentures IV QP LP			2. Issuer Name and Ticker or Trading Symbol Epizyme, Inc. [EPZM]				>	5. Relationship of Reporting Person(s) to Issuer			
(Last)				•				(Check all applicable)			
(3. Date of Earliest Transaction (Month/Day/Year) 02/10/2014				- - 1	Director _X_ 10% Owner Officer (give title _Other (specify below)			
				Amendment, Date Original (Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X_ Form filed by More than One Reporting 			
DOSTON,	WA 02110]	Person			
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative S	Securit	ties Acqu	ired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year		n Date, if	3. Transactio Code (Instr. 8) Code V	4. Securitie our Dispose (Instr. 3, 4) Amount	d of (I))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	02/10/2014			S	466,666 (<u>1)</u>	D	\$ 29.25	2,413,819	Ι	See footnote (2)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: KAILIAN VAUGHN M - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships					
Reporting Owner Mane / Maress	Director	10% Owner	Officer	Other		
MPM BioVentures IV QP LP C/O MPM ASSET MANAGEMENT 200 CLAREDON STREET, 54TH FLOOR BOSTON, MA 02116		Х				
Scopa James Paul C/O MPM ASSET MANAGEMENT 601 GATEWAY BLVD., SUITE 350 SOUTH SAN FRANCISCO, CA 94080		Х				
MPM Asset Management Investors BV4 LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116		Х				
MPM BioVentures IV GmbH & Co. Beteiligungs KG C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116		Х				
MPM BioVentures IV GP LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116		Х				
MPM BioVentures IV LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON, MA 02116		Х				
MPM BioVentures IV Strategic Fund, L.P. C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR		Х				

BOSTON, MA 02116			
Foley Todd C/O MPM ASSET MANAGEME 200 CLARENDON STREET, 54T BOSTON, MA 02116		х	
KAILIAN VAUGHN M C/O MPM ASSET MANAGEME 200 CLARENDON STREET, 54T BOSTON, MA 02116		х	
Signatures			
•	BioVentures IV LLC, the managin eral partner of MPM BioVentures IV	•	02/11/2014
	**Signature of Reporting Person		Date
/s/ James Scopa	**0' / (D / D		02/11/2014
	**Signature of Reporting Person		Date
By Luke Evnin, member of MPM Management Investors BV4 LLC	BioVentures IV LLC, the manager /s/ Luke Evnin	of MPM Asset	02/11/2014
	**Signature of Reporting Person		Date
•	BioVentures IV LLC, the managin aging limited partner of MPM BioV	•	02/11/2014
	**Signature of Reporting Person		Date
By Luke Evnin, member of MPM BioVentures IV GP LLC /s/ Luke	BioVentures IV LLC, the managin Evnin	g member of MPM	02/11/2014
	**Signature of Reporting Person		Date
By Luke Evnin, member of MPM	BioVentures IV LLC /s/ Luke Evn	in	02/11/2014
	**Signature of Reporting Person		Date
•	BioVentures IV LLC, the managin eral partner of MPM BioVentures IV	6	02/11/2014
	**Signature of Reporting Person		Date
/s/ Todd Foley			02/11/2014
	**Signature of Reporting Person		Date
/s/ Vaughn Kailian			02/11/2014
	<u>**</u> Signature of Reporting Person		Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares were sold as follows: 377,313 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 14,536 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG"), 10,729 by MPM Asset Management Investors BV4 LLC ("AM BV4") and 64,088 shares by MPM

(1) BioVentures IV Strategic Fund, L.P. ("BV IV SF"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP, BV IV KG and BV IV SF and BV LLC is the manager of AM BV4. Ansbert Gadicke, Luke Evnin, Vaughn M. Kailian, James Paul Scopa and Todd Foley are the members of BV LLC.

The shares are held as follows: 1,951,645 by BV IV QP, 75,188 by BV IV KG, 55,495 by AM BV4 and 331,491 shares by BV IV SF.

(2) Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

Remarks:

See Form 4 for Luke Evnin for additional members of this joint filing.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.